Alnylam Pharmaceuticals
ALNY
#564
Rank
ยฃ32.84 B
Marketcap
ยฃ247.62
Share price
0.51%
Change (1 day)
26.49%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Net assets

Net assets on the balance sheet as of December 2025 : ยฃ0.58 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company has ยฃ0.58 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Alnylam Pharmaceuticals - Net assets on balance sheet (from 2003 to 2025)

Net assets by year

Year Net assets Change
2025-12-31$ยฃ0.58 B996.14%
2024-12-31$ยฃ53.46 M-130.87%
2023-12-31$-ยฃ0.18 Billion32.42%
2022-12-31$-ยฃ0.14 Billion-130.01%
2021-12-31$ยฃ0.43 B-41.55%
2020-12-31$ยฃ0.74 B-32.05%
2019-12-31$ยฃ1.09 B6.97%
2018-12-31$ยฃ1.02 B-21.52%
2017-12-31$ยฃ1.30 B75.25%
2016-12-31$ยฃ0.74 B-12.61%
2015-12-31$ยฃ0.85 B41.92%
2014-12-31$ยฃ0.60 B266.92%
2013-12-31$ยฃ0.16 B97.61%
2012-12-31$ยฃ82.93 M9.25%
2011-12-31$ยฃ75.91 M-25.94%
2010-12-31$ยฃ0.10 B-6.8%
2009-12-31$ยฃ0.10 B-20.26%
2008-12-31$ยฃ0.13 B37.56%
2007-12-31$ยฃ0.10 B-2.39%
2006-12-31$ยฃ0.10 B186.68%
2005-12-31$ยฃ35.82 M49.06%
2004-12-31$ยฃ24.03 M-260.98%
2003-12-31$-ยฃ14.94 Million415.26%
2002-12-31$-ยฃ2.9 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
Novartis
NVS
ยฃ34.62 B 5,798.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ64.18 B 10,835.10%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ23.24 B 3,860.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ0.98 B 67.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
ยฃ51.34 M-91.25%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
ยฃ0.97 B 65.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ5.88 B 902.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.41 B-28.70%๐Ÿ‡บ๐Ÿ‡ธ USA